EU Falsified Medicines Directive
Article by Lynne Byers
With specific requirements relating to importation of APIs into the EU coming into effect in July 2013, I am sure companies who import APIs into the EU are aware of the implementation of the Falsified Medicines Directive.
Rx-360 has been tracking the legislative situation surrounding this directive, as well as the impact, and has now made this information available. Rx-360 first presented this information at the 1st February webinar which took place with about 140 people in attendance. The presentation, which can be accessed below, includes both the legislative situation and gives details of a survey which Rx-360 performed with both members and non-members. The survey identified those countries where APIs are manufactured and then imported into the EU and also the relative importance of each country in terms of potential impact to supply of APIs.
This event is one of many which demonstrate the value of Rx-360 membership - click here to contact us and become a member today.
View the EU Falsified Medicines Directive slides from Rx-360: